Anagrelide

• UNSPSC Description:

  Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action[1][2][3].

• Target Antigen:

  Apoptosis; Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/anagrelide.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1NC2=NC3=C(C(Cl)=C(Cl)C=C3)CN2C1

• Molecular Weight:

  256.09

• References & Citations:

  [1]Guosu Wang, et al. Comparison of the biological activities of Anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol. 2005 Oct;146(3):324-32.|[2]Y Hong, et al. Comparison between Anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of Anagrelide for the megakaryocytic lineage. Leukemia. 2006 Jun;20(6):1117-22.|[3]Olli-Pekka Pulkka, et al. Anagrelide for Gastrointestinal Stromal Tumor. Clin Cancer Res. 2019 Mar 1;25(5):1676-1687.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  68475-42-3